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Abstract
There have been recent efforts amongst immunologists to develop approaches for
following individual fish during challenges with viral and bacterial pathogens. This
study contributes to assessing the feasibility of using such approaches to study amoe-
bic gill disease (AGD). Neoparamoeba perurans, agent of AGD, has been responsible
for widespread economic and fish loss in salmonid aquaculture. With the emergence
of AGD in Europe, research into infection dynamics and host response has increased.
This study investigated the effect of repeat exposure to anaesthesia, a necessary
requirement when following disease progression in individual fish, on N. perurans. In
vitro cultures of N. perurans were exposed every 4 days over a 28-day period to
AQUI-S (isoeugenol), a popular anaesthetic choice for AGD challenges, at a concen-
tration and duration required to sedate post-smolt salmonids. Population growth was
measured by sequential counts of amoeba over the period, while viability of non-
attached amoeba in the culture was assessed with a vital stain. AQUI-S was found
to be a suitable choice for in vivo ectoparasitic challenges with N. perurans during
which repetitive anaesthesia is required for analysis of disease progression.
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1 | INTRODUCTION
With the continued expansion of the global aquaculture industry
(FAO, 2016), and related research on fish, there is a need for refine-
ment in experimental approaches, including analyses of in vivo
immune responses. A limited number of studies have been under-
taken in developing methodologies such as individual monitoring
(Collet et al., 2015; Monte, Urquhart, Secombes, & Collet, 2016;
Urquhart et al., 2016). Benefits of such approaches include a reduc-
tion in the number of animals required for challenge experiments
and higher quality data output, with reduced infection and response
variability (Collet et al., 2015). While previous individual monitoring
of fish following disease challenges has focused upon viral or bacte-
rial pathogens, attention must also turn to parasite studies in view of
serious parasite issues currently affecting aquaculture, for example
sea lice and amoebic gill disease (AGD) affecting salmonid farming
(Aaen, Helgesen, Bakke, Kaur, & Horsberg, 2015; Oldham, Rodger, &
Nowak, 2016). To assess the suitability of this methodology for
ectoparasites, Neoparamoeba perurans, the amoeboid aetiological
agent of AGD, was selected as a model due to its recent emergence
as a serious pathogenic threat to salmon aquaculture across northern
Europe.
The first occasion of AGD as an epizootic was observed in an
Atlantic salmon, Salmo salar, and rainbow trout, Oncorhynchus mykiss,
sea farm located in east Tasmania, during the summer of 1984–85
(Munday, 1986). It was suggested that the aetiological agent of AGD
could be classified as the normally free-living Neoparamoeba sp.
amoebae (Roubal, Lester, & Foster, 1989).
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However, failed attempts to induce AGD in laboratory exposures
with cultured Neoparamoeba pemaquidensis brought the validity of
the causative agent under question (Kent, Sawyer, & Hedrick, 1988;
Morrison, Crosbie, Cook, Adams, & Nowak, 2005). Young, Crosbie,
Adams, Nowak, and Morrison (2007) were able to determine the
true aetiological agent of AGD, as a newly described species Neop-
aramoeba perurans, which has since been cultured in vitro and used
to fulfil Koch’s postulates (Crosbie, Bridle, Cadoret, & Nowak, 2012).
To date, AGD is the most important disease associated with sal-
monid aquaculture in Australia, with reported losses of 10%–20%
annually in addition to (freshwater bathing) treatment costs (Munday,
Zilberg, & Findlay, 2001). Further cases of AGD in marine farmed
Atlantic salmon, the most susceptible species to the disease, have
been reported in Chile, with a 55.7% disease prevalence in the sum-
mer 2007–2008 (Bustos et al., 2011; Rozas, Bohle, Grothusen, &
Bustos, 2012); Canada (ICES, 2015); France; and Spain (Munday
et al., 2001; Rodger & McArdle, 1996) and a land-based partial recir-
culation system in South Africa during 2009–10 (Mouton, Crosbie,
Cadoret, & Nowak, 2014). In recent times, Northern Europe has suf-
fered increasing AGD prevalence with substantial economic and fish
stock losses. It was first described in eight farms in Ireland, in 1995
(Palmer, Carson, Ruttledge, Drinan, & Wagner, 1997; Rodger &
McArdle, 1996), then in Scotland, United Kingdom in 2006 (Young,
Dykova, Snekvik, Nowak, & Morrison, 2008), with typical losses
ranging from 10% to 20% but occasionally reaching 70% (Marine
Scotland 2012). In 2011, >25% of salmon aquaculture sites in Ireland
and Scotland reported AGD, with economic losses estimates at USD
$81M (Rodger, 2014; Shinn et al., 2015). Norwegian aquaculture has
seen mortalities ranging between 12% and 82%, and outbreaks have
increased from 5 in 2012, 56 in 2013 to 70 in 2014 (Powell, Rey-
nolds, & Kristensen, 2015; Steinum et al., 2008).
The recognized method of obtaining pathogenic samples of
N. perurans is to collect specimens from the gills of infected fish at
the point of lethal sampling (Morrison, Crosbie, & Nowak, 2004),
which involves at least one exposure to fish anaesthetic. Recent work
from Shijie, Adams, Nowak, and Crosbie (2016) has demonstrated that
a single exposure to anaesthetics containing eugenol did not inhibit
population growth or attachment abilities of cultured N. perurans.
To develop a non-lethal sampling approach requires repeated
anaesthesia of fish, which in turn, for an ectoparasitic disease model
such as AGD, also results in repeated anaesthesia of the pathogen.
Therefore, the first step in developing a non-lethal challenge model
for AGD is to examine the effect of repeat exposure of N. perurans
to anaesthesia.
AQUI-S is a gel-like anaesthetic that was first developed in
New Zealand in 1996. Inspired by the anaesthetic capabilities of
clove oil (eugenol), AQUI-S contains as active ingredient 50% isoeu-
genol (not present in natural clove oil) and 50% emulsifier polysor-
bate 80 (Javahery & Moradlu, 2012). It is the only registered food-
grade anaesthetic with zero withdrawal time in Australia, Chile,
Costa Rica, Honduras, Korea, and New Zealand; (AQUI-S, 2015). As
of 2014, AQUI-S has also been approved in Norway for sedation
and anaesthesia of Atlantic salmon and rainbow trout prior to and
during handling events, and in live fish transport (Kolarevic & Terje-
sen, 2014). AQUI-S was therefore selected due to the popularity of
use in countries most severely affected with AGD, alongside recent
findings of no short-term impacts upon attachment or viability of
N. perurans after single exposure (Shijie et al., 2016). This is the first
paper to report upon the repeated exposure of N. perurans to fish
anaesthetics and to describe any adverse effects found on this aqua-
culture ectoparasite.
2 | MATERIALS AND METHODS
2.1 | Preparation of flasks
A polyclonal culture of N. perurans, isolated and maintained at Mar-
ine Laboratory, Marine Scotland Science as described in Collins et al.
(2016), was used in experiments. The concentration of amoeba pre-
sent in a pooled seawater overlay of N. perurans in vitro cultures
was estimated as follows. Four 100 ll aliquots of amoeba culture
from the pooled culture overlay were added to a 96-well plate (Grei-
ner GMH) and three technical replicate 10-fold dilutions made from
each initial aliquot. The amoebae were allowed to settle in wells for
20 min and then counted with an inverted microscope. Means of
the counts, adjusted for dilution factor, were calculated and used to
estimate the number of amoebae in the pooled overlay.
Twelve 25-cm² tissue culture flasks (Greiner) with a malt-yeast
agar [MYA; 0.01% (w/v) malt extract, 0.01% (w/v) yeast extract, 2%
(w/v) bacteriological agar (Oxoid Ltd, UK)] under layer and a 7 ml
35ppt 0.22-lm-filtered (SteritopTM 0.22-lm polyethersulfone (PES)
membrane filters; Merck Millipore, Fisher Scientific) seawater overlay
were inoculated with approximately 1,500 amoebae/ml. Cultures
were stored in a 13°C incubator, and amoebae were left to adhere
overnight.
2.2 | Anaesthetic exposures
Six replicate flasks were used for each treatment: AQUI-S (isoeu-
genol) (AQUI-S New Zealand Ltd.) and control (35 ppt 0.22-lm-fil-
tered sea water). Anaesthetic treatment flasks were exposed to the
same concentrations and durations required to anaesthetize post-
smolt salmonids to Stage 4 anaesthesia, AQUI-S at 17 mg/L for
20 min. Due to the small amounts of anaesthetic required, at each
time point a stock solution was freshly prepared. An appropriate vol-
ume was dissolved in 35 ppt 0.22-lm-filtered sea water, pipetted
into the 7 ml seawater overlay to obtain the required concentration,
and the flasks agitated to ensure an even distribution of the anaes-
thetic across the culture.
After the predetermined exposure duration, the overlay contain-
ing the anaesthetic and the floating-form amoeba was transferred to
15-ml tubes, and the attached amoeba remaining in the flasks were
rinsed once with filtered sea water and 6.9 ml of filtered sea water
was provided to restore the overlay. Sea water used in the rinse was
discarded. The original overlay containing anaesthetic and floating-
form amoeba was centrifuged at 10739g for 10 min—it should be
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noted that this was additional contact time for the suspended
amoeba population with AQUI-S—the supernatant removed and
the amoebae present in the pellet transferred to a 1.5-ml Eppendorf
tube containing 1 ml filtered sea water. The amoeba suspensions
were centrifuged at 113379g for 1 min followed by the removal of
the supernatant and resuspension of amoeba in 1 ml filtered sea
water. Amoebae were washed a further time as above then returned
to their respective flasks after being resuspended in 100 ll filtered
sea water, returning the total overlay volume to 7 ml. Preliminary
work utilizing the vital stain Neutral Red (Sigma-Aldrich, N7005)
ascertained that the speed of centrifugation and transfer had no
negative effect upon the morphology or viability of the amoeba (al-
beit not amoebae exposed to anaesthetic) and that the speed and
duration of centrifugation were sufficient to pellet the suspended
amoeba from the suspension (data not shown). This process was also
carried out for all control flasks at each time point. All flasks were
returned to 13°C until the next scheduled exposure. Flasks were
treated with anaesthetic every 4 days for a 28-day period.
2.3 | Neoparamoeba perurans population growth
assessment
2.3.1 | Attached amoebae
Prior to seeding with amoebae, a transect was drawn diagonally
across the bottom of each culture flask with five indents, spaced at
1-cm intervals, extending from the top left corner to the middle of
the flask to standardize the position in flasks where amoebae counts
were obtained, and to help account for any potential differences
between different flask areas in amoebae settlement and growth.
Photographs of field of view were taken with an inverted micro-
scope at 910 magnification at each indent (n = 5) prior to each
anaesthetic exposure time point and attached amoebae counted
from photos. Attached amoebae counted were assumed alive due to
their ability to attach and their morphology.
2.3.2 | Suspended amoebae
For the viability assessment of amoebae in suspension, a 200 ll ali-
quot of the seawater overlay was removed from each flask prior to
each anaesthetic exposure time point; the seawater overlay of each
flask was gently agitated for approximately 5 s and the flask rotated
to an upright position so that the overlay pooled into the bottom
left corner of the flask to ensure the aliquot obtained was represen-
tative of the total overlay. This aliquot was then transferred to a
1.5-ml Eppendorf tube containing 4 ll of the vital stain Neutral Red.
The tubes were kept at 13°C for 40 min to allow the amoebae to
take up the stain. The cell suspensions were the centrifuged down
for 1 min at 113379g and the supernatant removed. The amoeba
pellets were next resuspended in 100 ll filtered sea water and 10 ll
of this suspension transferred to a well of a flat-bottomed 96-well
plate containing 90 ll sea water. Amoebae were left to settle in the
wells for 40 min and then were assessed for their viability with an
inverted microscope at 920 magnification. Viable amoebae had a
diverse morphology as well as obvious dye inclusions, while non-
amoebae had no visible dye inclusions and a spherical morphology
(Figure 1). Viable and non-viable amoebae were counted.
2.3.3 | MS-222 and metomidate flasks
The study also sought to assess the population growth and viability
of N. perurans following repeated doses of powder-based fish
anaesthetics metomidate (12.5 mg/L) (AquaCalmTM Western Chemi-
cal Inc.) and MS-222 (80 mg/L) (Sigma-Aldrich). These treatments
were carried out following the same methodology as detailed
above for the AQUI-S flasks. Due to the short exposure duration
required for in vivo sedation, three and five minutes, respectively,
the additional ten-minute exposure of the suspended amoeba dur-
ing the 10739g centrifugation of the anaesthetic-containing overlay
and wash stage renders the total exposure time for these
suspended populations 94 and 93 longer than required for a non-
lethal sampling procedure, and thus, these results should be inter-
preted with caution.
2.4 | Statistical analysis
Population growth data were analysed with the statistical software
package R (R Core Team, 2016). Total population count was con-
structed by combining mean count per field of view of attached
amoeba and mean count of both viable and non-viable amoeba in
the 200 ll aliquot of seawater overlay. Data concerning attached
population growth were subset into respective time points and
(a) (b) (c)
F IGURE 1 (a) Non-viable N. perurans
trophozoite after exposure to Neutral Red
vital stain, showing characteristic spherical
shape and absence of dye inclusions. (b)
Viable floating trophozoite after Neutral
Red exposure, with dye inclusions within
lysosomes. (c) Viable attached amoeba
after Neutral Red exposure
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analysed with a generalized linear mixed-effects model (GLMM) with
Poisson errors, with “Field Of View” as a fixed effect and “Flask”
treated as a random effect to account for overdispersion, utilizing
the statistical package “lme4” (Bates, Maechler, Bolker, & Walker,
2015). Data concerning suspended population counts were treated
as above, minus the absent “Field of View” additions. Suspended
amoeba percentage data were subset into respective time points
and analysed with a linear model.
3 | RESULTS
3.1 | AQUI-S population growth analysis
There were no statistically significant differences between the total
(attached and suspended) population growth of the AQUI-S-treated
amoebae and the control amoebae for the duration of the experi-
ment, aside from day 4 (p ≤ .01) and day 24 (p ≤ .05) when the
AQUI-S-treated flasks had significantly lower total amoebae popu-
lations when compared to control flasks (Figure 2). When assessing
the total attached population growth, AQUI-S treatment showed
significantly higher (p ≤ .05) populations of attached amoeba on days
12 and 20 (Figure 3) compared to the control. In contrast to this, on
days 12–28, AQUI-S-treated flasks had significantly lower popula-
tions of amoeba in suspension when compared to the controls
(Figure 3).
3.2 | AQUI-S non-viable population analysis
No statistical difference was seen in non-viable amoebae percentage,
in relation to the total amoebae population, in the AQUI-S treat-
ment when compared to the control, with the exception of day 20
(p < .05) where higher numbers of non-viable amoebae were found
in the AQUI-S treatment (Figure 4). When considering percentage
of non-viable amoebae in only the suspended amoeba population,
AQUI-S flasks had significantly higher percentages of non-viable
amoebae on days 4, 20 and 28 when compared to control flasks
(Figure 5).
3.3 | MS-222 and metomidate population growth
analysis
From Day 4, total population counts for both MS-222 and metomi-
date treatments were significantly lower (p ≤ .001) when compared
to controls (Figure 2). Total amoebae population counts for both
remained significantly lower than control flasks throughout the rest
of the experiment. Attached amoebae populations in the MS-222
and metomidate treatments mirror that of the total population
counts; from day 4 onwards, with counts in both treatments remain-
ing significantly lower (p ≤ .001) when compared to controls
(Figure 3).
F IGURE 2 Mean counts of total amoeba populations
(attached + suspended, viable + non-viable). Totals were constructed
from mean field of view of attached amoeba counts and numbers of
suspended amoebae isolated in 200 ll aliquots taken from seawater
overlay of the cultures. Where significance asterisks for both MS-
222 and metomidate are parallel, MS-222 asterisks are represented
on the left and metomidate on the right. Data are means  SE.
*p < .05, **p < .01, ***p < .001
F IGURE 3 (a) Mean counts of attached amoeba constructed
from mean field of view. (b) Mean count of total amoeba present in
the suspended amoeba population isolated in 200 ll aliquots taken
from seawater overlay of the cultures. Data are means  SE.
*p < .05, **p < .01, ***p < .001
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Following the first dose of anaesthetics (day 4), the populations
of suspended amoebae mirror those of the attached populations,
that is an initial reduction and statistically significant decrease in sus-
pended population counts in comparison with the suspended amoe-
bae in control and AQUI-S flasks, with no recovery in numbers
throughout the rest of the experiment. Prior to exposure to their
respective anaesthetics at Day 0, both MS-222 and metomidate
flasks were found to have significantly higher (p ≤ .001) amoebae in
suspension compared to the AQUI-S and control (Figure 3). There
were no significant differences found at Day 0, with respect to
attached amoebae numbers, between any of the treatments and
control (Figure 3). All amoebae were left to adhere overnight before
treatment at Day 0, at the same temperature, in the same incubator
in the agar base and seawater overlay derived from the same stocks.
Therefore, it is not possible to suggest a lack of adherence by the
amoeba due to culture differences in these treatments.
3.4 | MS-222 and metomidate non-viable
population analysis
After the second dose of anaesthetics (day 8), the percentage of
non-viable amoebae in both total and suspended populations in MS-
222 and metomidate flasks were significantly higher (p < .001) when
compared to the control, (Figures 4 and 5). In the suspended popula-
tions (Figure 5), there was a sustained increase in percentage of
non-viable amoebae throughout the rest of the experiment for both
these treatments, in which all timepoints remained significantly dif-
ferent (p < .001) to the control. This trend is also seen for the non-
viable amoebae percentage in relation to the total population for
MS-222 and metomidate (Figure 4), with sustained, significantly
higher percentages of non-viable amoebae when compared to the
control after day 8.
4 | DISCUSSION
Parasitic diseases are a major bottleneck in salmonid aquaculture,
with intense efforts to study the host–parasite interactions to find
effective treatments. To obtain non-lethal samples (sequential) from
fish during an in vivo challenge, the use of anaesthetic is unavoid-
able (Zahl, Samuelsen, & Kiessling, 2012). Therefore, the first step
taken towards establishing a non-lethal sampling challenge model is
to ascertain any inhibitory or assistive effect of the anaesthetic upon
the chosen parasite. If any effect were to be present, the methodol-
ogy would thus no longer be a true representation of the natural
experimental parasite infection for each fish, detected immune
responses, or pathology.
AQUI-S-treated amoebae show rapid growth in total population
in vitro from day 0 to 8 followed by a steady decrease in population
as seen in the control (Figure 2). When comparing the suspended
and attached population data (Figure 3), a relationship of AQUI-S
exposure and amoebae attachment is suggested. At day 12, mean
numbers of attached amoebae in the controls drop to approximately
one third of their day 8 mean numbers (from 296  16 to
116  14); concurrently, the control populations of amoebae in sus-
pension rose by a similar amount (from 92  16 to 254  16).
These data suggest that at day 12 there is a natural emigration of a
substantial proportion of attached amoebae population into the sea-
water overlay. This movement was not observed in the AQUI-S
flasks, which showed significantly higher populations of attached
amoebae at days 12 and 20, and sustained significantly lower amoe-
bae populations in suspension from day 12 (Figure 3) although over-
all amoebae numbers (attached + suspended) remained similar
between AQUI- S treatment and control. This infers that with
repeated exposure to AQUI-S, an increased proportion of amoeba
remain attached to their substrate; however, current AGD literature
F IGURE 4 Mean percentage of non-viable amoebae present in
the total amoeba population calculated from mean field of view
counts of attached amoeba and suspended amoebae isolated in
200 ll aliquots taken from seawater overlay of the cultures. Data
are means  SE. *p < .05, **p < .01, ***p < .001
F IGURE 5 Mean percentage of non-viable amoeba present in the
suspended amoeba population isolated in 200 ll aliquots taken from
seawater overlay of the cultures. Data are means  SE. *p < .05,
**p < .01, ***p < .001
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offers no hypothesis as to why this effect may be seen. During
in vivo challenge experiments, an artificially elongated duration of
attachment, during which parasitic amoeba could theoretically spend
more time colonizing the gill substrate (Wiik-Nielsen et al., 2016)
than completing the natural emigration to the surrounding sea water,
may lead to an increased level of disease progression and therefore
an elevated immune response, which may not be comparable to the
speed of disease progression found in the field. Nonetheless, with
reported loss of virulence seen in cultured N. perurans possibly due
to lack of attachment to gills (Bridle, Davenport, Crosbie, Polinski, &
Nowak, 2015), increased attachment due to the use of isoeugenol-
based anaesthetics may help mitigate this problem, if similar attach-
ment processes are involved.
In this study, the amoebae were classed as “non-viable” primarily
due to the lack of uptake of the Neutral Red vital stain (Repetto, Del
Peso, & Zurita, 2008), but morphology was also taken into consider-
ation. Amoebae in which no stain was seen all held the same spheri-
cal morphology (Figure 1), characteristic of in vitro cultures with a
suboptimal subculturing schedule, suggesting this morphology is a
response to overcrowding, lack of nutrients or environmental stres-
sors (Lima, Taylor, & Cook, 2017; Wiik-Nielsen et al., 2016). As the
cultures in this study were washed regularly at 4-day intervals, and
percentage of non-viable amoebae were higher in cultures with
lower amoebae numbers (Figures 2 and 4), it is unlikely that the
spherical morphology was caused by a build-up of waste products
from the amoebae themselves, or overcrowding, but more likely a
response to anaesthetic exposure, or possibly limiting factors associ-
ated with the culture medium nutrients. The effect of the different
anaesthetics, if any, on bacteria in the non-xenic cultures, on which
the amoebae may feed, was not recorded.
Recent work from Shijie et al. (2016) found that AQUI-S at
varying concentrations showed no significant effect on the viability
or attachment capabilities of N. perurans 2 hr after single treatment.
While working within the range of concentrations selected by Shijie
et al. (2016) at 17 mg/L, this study was able to monitor viability of
amoebae over a longer period (4 days after each treatment), allowing
for a more comprehensive view of any possible impacts. With the
exception of day 20, where there was a small but significant
(p < .05) rise in the percentage of non-viable amoebae in the total
population compared to control (Figure 4), AQUI-S-treated amoe-
bae remained statistically similar to those counted in the control,
with non-viable amoebae remaining a small proportion (<10%) of the
total amoebae population. This suggests that repeated exposure of
AQUI-S has no significant effect on the viability of N. perurans.
However, when comparing percentages of non-viable amoebae
as part of the suspended population, significant differences were
found between the control and AQUI-S populations at days 4, 20
and 28 (Figure 5), but as discussed above this reflects greater num-
bers of amoebae remaining attached in the AQUI-S flasks, resulting
in non-viable amoebae forming a higher percentage of total sus-
pended cells.
After a single exposure timepoint MS-222, metomidate-based
anaesthetics seem to have a strong inhibitory effect upon both the
growth of attached in vitro N. perurans cultures and a detrimental
effect on viability of floating-form amoeba after repeated exposure.
As previously highlighted, the suspended amoebae in metomidate
and MS-222 flasks were in contact with their anaesthetics for sub-
stantially longer than required for in vivo anaesthetization. This
increase in exposure time must be taken into consideration when
evaluating the outcomes of the attached amoeba growth, as both
populations are interdependent (Crosbie et al., 2012). However, it
should also be considered that during an individually monitored chal-
lenge, fish are sampled with an in-tank anaesthesia methodology
(Collet et al., 2015), wherein the suspended amoeba will remain in
contact with the anaesthetic while Stage 4 anaesthetized fish are
netted out, processed and placed in a smaller recovery tank followed
by the initial tank being drained with a flow-through system. Any
amoeba which remains in this tank after draining and refilling will
have also been exposed to whichever anaesthetic was used for a
longer duration that initially required for Stage 4 anaesthesia. Previ-
ous studies investigating adherence behaviour of N. perurans have
shown high-density colonization of aquarium surfaces, highlighting
their potential as areas for attachment and replication (Rolin, Gra-
ham, McCarthy, Martin, & Matejusova, 2016) and may therefore act
as an additional source of infection over time; however, the impact
of amoebae shed from gills in reinfection and disease progression
over the challenge, if any, is not known. It could be argued that this
prolonged exposure of anaesthetics to the suspended amoeba popu-
lation may even be more representative of the environmental condi-
tions during non-lethal sampling.
Metomidate is able to block the synthesis of plasma cortisol by
inhibiting the mitochondrial cytochrome P450-dependent enzymes
required to catalyse the glucocorticoid (Small, 2003), an effect which
has also been reported in fish treated with MS-222 (Chevion, Stege-
man, Peisach, & Blumberg, 1977; Fabacher, 1982). Akinrotimi, Gab-
riel, and Orokotan (2013) have shown that metomidate also has the
dose-dependent ability to impair the activities of plasma enzymes
such as transaminases in the African sharptooth catfish, Clarias
gariepinus, with the highest level of impairment seen at 12 mg/L.
MS-222 has been shown to inhibit the growth of Gram-negative
bacteria (Fedewa & Lindell, 2005); however, the concentrations
(5,000–200 mg/L) used in this latter study were far higher than
those used in vivo. Similar inhibitory effects on N. perurans p450
pathway and transaminases may have played a role in the suppres-
sion of population growth, attachment and viability of amoebae in
the flasks treated with these anaesthetics (Figures 2, 3, 4 and 5).
Such impacts may not be seen during in vivo challenges due to
shorter exposure periods of fish to anaesthetics; therefore, the suit-
ability of MS-222 and metomidate as anaesthetics for non-lethal
sampling AGD challenges should be investigated further, with more
efficient cleaning of the suspended population, utilizing faster spin
times or filtering methods to obtain more appropriate exposure
times.
In conclusion, this study illustrates the importance of selecting an
appropriate anaesthetic when working with ectoparasites. Isoeu-
genol-based, specifically AQUI-S, anaesthetics are suitable for both
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harvesting and repeated exposure in vivo and in vitro for work with
the ectoparasite N. perurans.
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